Antinociceptive Effect of the Combination of a Novel α4β2* Agonist with Donepezil in a Chronic Pain Model
Authors:
- Fernanda B. de M. MonteFMFernanda B. de M. Monte
- Tadeu L. MontagnoliTadeu L. Montagnoli
- Bruno E. DemattéBDBruno E. Dematté
- Fernanda GubertFGFernanda Gubert
- Vitória S. VenturaVVVitória S. Ventura
- Jaqueline S. da SilvaJSJaqueline S. da Silva
- Margarete M. TrachezMTMargarete M. Trachez
- Rosalia Mendez-OteroRMRosalia Mendez-Otero
- Gisele Zapata-SudoGZGisele Zapata-Sudo
Open Access
- 8 December 2023
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 11 (12) , 3249
Abstract
Chronic pain presents a major challenge in contemporary medicine, given the limited effectiveness and numerous adverse effects linked to available treatments. Recognizing the potential of the cholinergic pathway as a therapeutic target, the present work evaluates the antinociceptive activity of a combination of Cris-104, a novel α4β2* receptor agonist, and donepezil, a central anticholinesterase agent. Isobolographic analysis revealed that equimolar combination was approximately 10 times more potent than theoretically calculated equipotent additive dose. Administration of Cris-104 and donepezil combination (3 μmol/kg) successfully reversed hyperalgesia and mechanical allodynia observed in rats subjected to spinal nerve ligation (SNL). The combination also modulated neuroinflammation by reducing astrocyte activation, evident in the decreased expression of glial fibrillary acidic protein (GFAP) in the spinal cord. The observed synergism in combining a nicotinic receptor agonist with an anticholinesterase agent underscores its potential for treating chronic pain. This alternative therapeutic distinct advantage, including dose reduction and high selectivity for the receptor, contribute to a more favorable profile with minimized adverse effects.Keywords
Funding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) (#E-26/200.881/2021)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq,) (#E-26/200.881/2021)
- Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (#E-26/200.881/2021)
- Cristália Produtos Químicos e Farmacêuticos Ltda (#E-26/200.881/2021)
This publication has 29 references indexed in Scilit:
- α4β2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for painEuropean Journal of Pharmacology, 2013
- Animal models of schizophreniaBritish Journal of Pharmacology, 2011
- The evidence for pharmacological treatment of neuropathic painPain, 2010
- Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent painPain, 2010
- Multiplicative interactions to enhance gabapentin to treat neuropathic painEuropean Journal of Pharmacology, 2008
- Oral Gabapentin Activates Spinal Cholinergic Circuits to Reduce Hypersensitivity after Peripheral Nerve Injury and Interacts Synergistically with Oral DonepezilAnesthesiology, 2007
- Oral Donepezil Reduces Hypersensitivity after Nerve Injury by a Spinal Muscarinic Receptor MechanismAnesthesiology, 2007
- The role of sodium channels in neuropathic painSeminars in Cell & Developmental Biology, 2006
- Donepezil: a reviewExpert Opinion on Drug Metabolism & Toxicology, 2005
- The safety and tolerability of donepezil in patients with Alzheimer's diseaseBritish Journal of Clinical Pharmacology, 2004